Navigation Links
Quest Diagnostics to Release Second Quarter 2008 Financial Results
Date:7/10/2008

MADISON, N.J., July 10 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that its second-quarter 2008 results will be made public on Tuesday, July 22, before the market opens, and that it will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day.

The public may access the conference call through a live audio webcast available on Quest Diagnostics' Investor Relations link on the Internet at http://www.questdiagnostics.com/investor.

The conference call can also be accessed by dialing 210-839-8500, passcode 3214469. The company suggests participants dial in approximately 10 minutes before the call. Please note that this feature will be in listen-only mode.

A replay of the call may be accessed through the Internet at http://www.questdiagnostics.com/investor or by dialing 800-284-7027, or 402-220-9738 for international callers. No access code will be required. Telephone replays will be available from 10:30 a.m. ET on July 22 until midnight ET on August 19, 2008.

Anyone listening to the Quest Diagnostics call is encouraged to read Quest Diagnostics' periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The com
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... WARREN, N.J. , Aug. 26, 2015  Roka ... company focused on providing advanced testing solutions for the ... Thomas, CEO will present at the Sidoti & Company ... The conference will be held at the New York ... the presentation will be available through the investor relations ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
(Date:8/26/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has been informed that Magnum Opus 2 ... Mr. Yuen Kam, chairman of the board of directors ... "Shares") of  Excellent China Healthcare Investment Limited ("KKR SPV") ...
(Date:8/26/2015)... ... ... PRC Clinical, a Clinical Trial Management Expert CRO, will be ... California. The Clinical Trial Management Expert CRO seeks to introduce more California-based sponsors to ... , Stem Cell Meeting on the Mesa on October 7-9 in ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Receive Funding, From Allied Minds to Commercialize Novel Technology for the ... ... Aliquots, BOSTON, July 2 Allied Minds, a pre-seed investment,corporation ... Development, and Northeastern,University announce the creation of CryoXtract Instruments, LLC, a ...
... levels as a possible ... predictor of clinical activity -, TORONTO, ... ("Lorus" or the "Corporation"), a biopharmaceutical company,specializing in the research ... cancer, today announced publication by,an Ohio State University (OSU) clinical ...
... Microfluidic Systems Inc.,(MFSI) announced today that it has ... of Microfluidic - Bioagent Autonomous Networked Detector,(M-BAND). This ... funded phases by the DHS,Science and Technology Directorate ... allow for low-volume production of automated,systems for extended ...
Cached Biology Technology:Investment Firm Allied Minds to Commercialize New Frozen Aliquotter Technology with Two Local Major Universities. 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 3Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 5Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 2Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 3
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/12/2015)... , Aug. 12, 2015  New research unveiled ... attack Android phones to steal users, fingerprints. Information ... availability of fingerprint scanners on mobile devices, making ... To secure biometrics on mobile devices, HYPR Corp. ... these convenient authentication systems with strong cryptographic security. ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... the form of tiny grains resembling powder, which is ... from the European Synchrotron Radiation Facility (ESRF) and the ... the synchrotron to determine the structure of microcrystal grains ... a thousand on the size of the analysable samples, ...
... may help reduce the risk of pancreatic cancer, says ... found naturally in apples and onions, has been identified ... and reducing the risk of pancreatic cancer. Although ... smokers who consumed foods rich in flavonols had a ...
... Children,s Research Hospital settled a century-old debate on the ... and capillaries critical to various essential housekeeping functions in ... development of new therapies for lymphatic system disorders, the ... various mouse models to demonstrate that the lymphatic vasculature ...
Cached Biology News:Unveiling the structure of microcrystals 2Naturally-occurring apple compounds reduce risk of pancreatic cancer 2St. Jude settles century-old debate on origin of mammalian network of lymphatic vessels 2St. Jude settles century-old debate on origin of mammalian network of lymphatic vessels 3
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
... Protein Staining Solution stains proteins ... electrophoresis (detection limit >= 8 ng ... including washing and destaining processes can ... staining of gel (20 min), proteins ...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Biology Products: